Akademisyen
SERKAN YILDIRIM
DOKTOR ÖĞRETİM ÜYESİ (Unvan:Doçent)
SELÇUK ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Tıbbi Onkoloji (İç Hastalıkları)
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 26
- Proje 0
- Kitap 3
- Bildiri 0
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
0
Q2
3
Q3
5
Q4
2
WoS (JCR)
Q1
1
Q2
2
Q3
2
Q4
6
TR Index
7
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
0
Ort. yüzdelik
35.1%
Üst %1 payı
0.0%
Üst %10 payı
0.0%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2025 Enhanced antitumor effects of interferon-stimulating DNA and magnetic hyperthermia in a breast cancer rat model YÖKSİS SJR Q2 JCR Q1 OpenAlex 55.7%
- 2025 Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety YÖKSİS JCR Q2 OpenAlex 44.6%
- 2023 Effect of Upfront Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer Patients with Gleason Grade Group 5 YÖKSİS SJR Q3 JCR Q3 OpenAlex 24.6%
- 2023 Second-Line Chemotherapy in Gastric Cancer: a Retrospective Study YÖKSİS SJR Q3 JCR Q4 OpenAlex 55.1%
- 2022 Inflammatory Prognostic Index in Metastatic Renal Carcinoma Treated with Nivolumab YÖKSİS SJR Q3 JCR Q4 OpenAlex 69.4%
- 2022 Kastrasyon Duyarlı Metastatik Prostat Kanserinde İki Prognostik Belirteç: ALP ve Gleason Skoru YÖKSİS OpenAlex 5.5%
- 2022 Metastatik mide kanserinde karsinoembriyonik antijen (cea) prediktif midir? YÖKSİS TR Index OpenAlex 3.6%
- 2022 Kronik Lenfositik Tiroiditli Olgular ve Normal Populasyonda D Vitamini Düzeylerinin Karşılaştırılması ve Otoimmünite Üzerindeki Rolü YÖKSİS TR Index SJR Q4 OpenAlex 14.0%
- 2022 title Zaprinast and avanafil increase the vascular endothelial growth factor, vitamin D sub3/sub , bone morphogenic proteins 4 and 7 levels in the kidney tissue of male rats applied the glucocorticoid/title YÖKSİS SJR Q2 JCR Q2 OpenAlex 58.3%
- 2021 Is FOLFIRINOX Better In Primary Resected Metastatic Pancreatic Cancer ? YÖKSİS TR Index OpenAlex 45.3%
- 2021 Metastatic Pancreatic Cancer Second-Line Treatment Options: Is the Difference Only in Cost? YÖKSİS SJR Q3 JCR Q4 OpenAlex 0.3%
- 2015 Adjuvant Chemotherapy and Prognostic Factors in Stage II Colon Cancer - Izmir Oncology Group Study YÖKSİS SJR Q2 JCR Q3 OpenAlex 70.8%
- 2022 Trıplet or Doublet Chemotherapy Regimens in Metastatic Gastric Cancer YÖKSİS OpenAlex 65.4%
- 2022 Predictive Value of Lymphocyte-Related Blood Parameters of before Ado-Trastuzumab Emtansin Treatment in Breast Cancer YÖKSİS TR Index OpenAlex 5.6%
- 2022 Options in First Line Management of Metastatic Pancreatic Cancer and the Determinative Role of ECOG Performance Status YÖKSİS TR Index OpenAlex 37.9%
- 2021 Palliative Biliary Drainage Has No Effect on Survival in Pancreatic Cancer: Medical Oncology Perspective YÖKSİS SJR Q3 JCR Q4 OpenAlex 18.0%
- 2021 Are Hormonal Agents Better Than Chemo in Metastatic Castration-resistant Prostate Cancer? YÖKSİS TR Index SJR Q4 JCR Q4 OpenAlex 29.7%
- 2021 Evaluation of Castration-Resistant Elderly Patients YÖKSİS TR Index OpenAlex 12.0%
- 2021 Pancreatic cancer patients who cannot undergo curative surgery live as much as patients over 70 years old YÖKSİS JCR Q4